Investor Advent Life Sciences LLP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Advent Life Sciences LLP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2024-08-20 13D/A ELOX / Eloxx Pharmaceuticals, Inc. 2,532,270 124,972
2022-02-14 13G AURA / Aura Biosciences, Inc. 2,023,857 2,023,857
2022-02-14 13G/A AFIB / Acutus Medical, Inc. 1,619,371 1,619,371
2021-04-13 13D ELOX / Eloxx Pharmaceuticals, Inc. 2,532,270
2021-02-10 13G AFIB / Acutus Medical, Inc. 1,619,371
2021-02-10 13D/A ITRM / Iterum Therapeutics plc 879,402 2,890,085
2020-02-11 13G/A AXNX / Axonics, Inc. 1,696,849 1,273,859
2020-01-29 13D/A ITRM / Iterum Therapeutics plc 868,161 879,402
2019-02-11 13G AXNX / Axonics, Inc. 1,696,849
2018-06-11 13D ITRM / Iterum Therapeutics plc 868,161 868,161
2018-06-08 13D ITRM / Iterum Therapeutics plc 868,161
2018-02-08 13G ARAV / Aravive, Inc. 2,313,295 1,692,753
2017-02-10 13G ARAV / Aravive, Inc. 2,288,328 2,313,295
2016-02-26 13G ARAV / Aravive, Inc. 2,288,328
2015-02-17 13G ARAV / Aravive, Inc. 2,216,558